4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Cambridge, United States with about 136 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, AMLX reported $0M in revenue and ($145M) in net income.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $87M | $381M | $22M | — |
| Gross Profit | $0M | ($37M) | $355M | $19M | — |
| Operating Income (EBIT) | ($153M) | ($256M) | $39M | ($201M) | — |
| Net Income | ($145M) | ($302M) | $49M | ($198M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($44M) | ($37M) | ($36M) | ($43M) | ($38M) | — |
| Net Income | ($41M) | ($33M) | ($34M) | ($41M) | ($36M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $333M | $194M | $518M | $392M | — |
| Total Liabilities | $27M | $29M | $84M | $51M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AMLX viewer.
About TickerBase · Data methodology & sources